Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on November 2, 2009. The report addresses a corporate governance event rather than financial performance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding personnel changes and does not contain financial statements.
Material Changes
The material change reported is the resignation of Dr. Thomas Monath as a director of Novavax, Inc., effective November 2, 2009. At the time of his resignation, Dr. Monath served on both the Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Dr. Thomas Monath resigned from the Board of Directors on November 2, 2009.
- Dr. Monath was a member of the Compensation Committee and the Nominating and Corporate Governance Committee.
- The report was signed by Frederick W. Driscoll, Vice President, Chief Financial Officer and Treasurer, on November 5, 2009.